Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth

Paediatrics and Child Health

Volumn 16, Issue 9, 2011, Pages 575-580

  Ho, Josephine ^a,d   Panagiotopoulos, Constadina ^b   McCrindle, Brian ^c   Grisaru, Silviu ^a,d   Pringsheim, Tamara ^d   Belanger, Stacey ^e   Casselman, Lisa ^f   Davidson, Jana ^b   Doja, Asif ^g   Jabbal, Rekha ^h   MacKean, Gail ^f   McLennan, John ^d   Palda, Valerie ^c   Patten, Scott ^d   Pearce, Michelle ^c   Ponesse, Jonathan ^g   Thomas, Roger ^d   Waheed, Waqar ^d   Wilkes, Chris ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Mental Health Commission of Canada   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Antipsychotic medications; Children; Metabolic syndrome

Indexed keywords

CLOZAPINE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; THYROTROPIN; UNCLASSIFIED DRUG; ZIPRASIDONE;

BODY MASS; DIASTOLIC BLOOD PRESSURE; DRUG USE; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HUMAN; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MEDICAL SPECIALIST; METABOLIC DISORDER; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THYROID GLAND; THYROID GLAND EXAMINATION; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80655145927     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669-77.
2. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006;163:402-10. (Pubitemid 44469381)
3. Lindsay RL, Leone S, Aman MG. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr 2004;43:437-44. (Pubitemid 38781316)
4. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 2009;194:158-64.
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73.
6. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63:524-9. (Pubitemid 351220784)
7. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009(4):CD006627.
8. A health professional's guide to using growth charts. Paediatr Child Health 2004;9:174-88.
9. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:S1-13.
10. Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev 2009(1):CD001872.
11. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry 2006;67:1253-60. (Pubitemid 44439698)
12. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophrenia Res 2007;91:169-77.
13. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Res 2006;83:95-101.
14. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008;29:1130-4.
15. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-9. (Pubitemid 46114226)
16. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7. (Pubitemid 34274950)
17. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009;19:275-9.
18. Maayan L, Vakhrusheva J, Correll C. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-30.
19. Douketis JD, Paradis G, Keller H, Martineau C. Canadian guidelines for body weight classification in adults: Application in clinical practice to screen for overweight and obesity and to assess disease risk. CMAJ 2005;172:995-8. (Pubitemid 40546592)
20. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl):555-76.
21. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-S201.
22. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208.
23. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67. (Pubitemid 46598908)
24. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-38.
25. McCrindle BW. Pathogenesis and Management of Obesity-Related Dyslipidemia. In: Freemark M, ed. New York: Humana Press (In press).
26. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61. (Pubitemid 29047332)
27. Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002;12:83-91. (Pubitemid 34779022)
28. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009;19:403-14.
29. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 2004;64:2291-314. (Pubitemid 39388605)
30. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:714-7.